表紙
市場調查報告書
商品編碼
1071623

乳癌抗體與生物標記臨床試驗市場:2028年

Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028

出版日期: | 出版商: Biomarkers Insights | 英文 3900 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介
本報告提供全球乳癌抗體生物標記臨床試驗市場相關調查,單株抗體,抗體藥物複合體,組合抗體的概要與臨床試驗趨勢,及加入此市場的主要企業競爭情形等資訊。

目錄

第1章 全球乳癌抗體市場

  • 目前市場情境
  • 未來市場機會

第2章 乳癌的單株抗體-可得性,專利,價格及劑量的分析

  • Trastuzumab(Herceptin)
  • Trastuzumab生物相似藥(Ontruzant)
  • Trastuzumab生物相似藥(Ogivri)
  • Trastuzumab生物相似藥(Herzuma)
  • Trastuzumab生物相似藥(Trazimera)
  • Trastuzumab生物相似藥(Kanjinti)
  • Trastuzumab生物相似藥(Zercepac/HLX02)
  • Pertuzumab(Perjeta)
  • Margetuximab (Margenza)
  • Pembrolizumab (Keytruda)
  • Atezolizumab (Tecentriq)
  • Inetetamab (Cipterbin)

第3章 乳癌抗體藥物複合體-可得性,劑量及價格分析

  • Kadcyla
  • Enhertu
  • Trodelvy
  • Ujvira

第4章 組合抗體-可得性,劑量,價格及銷售分析

  • Trastuzumab,Pertuzumab,及玻糖醛酸酶(Phesgo)
  • Trastuzumab與玻糖醛酸酶注射(hasepuchinhairekuta)

第5章 乳癌單株抗體-銷售額分析

  • Herceptin
  • Kanjinti
  • Pertuzumab
  • Margenza
  • Keytruda
  • Atezolizumab
  • Trazimera
  • Phesgo

第6章 乳癌抗體藥物複合體-銷售趨勢

  • Kadcyla
  • Enhertu
  • Trodelvy

第7章 乳癌抗體生物標記和臨床試驗趨勢,各企業,各適應症,各相

  • 研究
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 預註冊
  • 登記完畢

第8章 上市完畢的乳癌抗體生物標記趨勢

第9章 競爭情形

  • Amgen
  • Akesobio
  • Beigene
  • Gilead Sciences
  • Macrogenics
  • Merck
  • Pfizer
  • Roche
  • Samsung Bio
  • Zydus Cadila
目錄

“Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report” Highlights:

  • Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
  • Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
  • Breast Cancer Biomarkers Sourced During Clinical Trials
  • Breast Cancer Biomarkers Insight By Antibodies Classification
  • Insight On Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Antibody
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

The introduction of biomarker has shown to have critical role in the diagnosis and management of cancer. In advancement towards precision medicine, the field of cancer biomarker discovery has rapidly expanded over the last few decades. This has been developed by advances in technologies and approaches including next generation sequencing, mass spectrometry, circulating tumor cells, and cell-free DNA. The discovery and use of specific prognostic and predictive biomarkers have enabled the application of targeted precision therapies to specific molecular subgroups of patients likely to gain benefit. Within breast cancer, recent biomarker discovery efforts have led to the identification and development of several prognostic and predictive biomarkers including multigene signatures.

Till date, three most important biomarkers for breast cancer are estrogen receptor (ER), progesterone receptor (PR) and a receptor called HER2. The levels of these markers can influence how a person with breast cancer is treated in the clinic. Despite these advances, there is still an important clinical need for the development and validation of novel biomarkers with greater sensitivity, specificity, and clinical utility. Among all targeted therapies, immunotherapy is gaining considerable interest for the management of breast cancer. So far, the typical biomarkers like PD-L1 expression and the numbers of immune cells in the tumor are used for identifying potential patients for the therapy.

The high adoption rates of immunotherapeutic approaches in breast cancer management has surged the further research and development activities in breast cancer biomarker market. Currently, large number of ongoing clinical trials is validating the role of novel biomarkers for breast cancer immunotherapy approaches. Recently a study demonstrated that a molecule called the Major Histocompatibility Complex Class II protein (MHC-II), has the potential to be a predictor of immunotherapy benefit with two types of breast cancer including early-stage, triple negative breast cancer (TNBC) and high-risk, oestrogen receptor-positive breast cancer (HR+) when expressed on breast cancer cells. The findings of the association with response in early-stage high-risk HR+ patients suggests that MHC-II may be a useful tool in a broader context for breast cancer and this area would benefit from further study.

As per our report findings, the global breast cancer antibodies market will surpass US$ 15 Billion by 2028. The increasing prevalence of breast cancer is a prime factor boosting the cancer biomarkers market growth. In addition to this, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various breast cancer subtypes. Additionally, many pharmaceutical companies are investing massive amounts into research and development of novel biomarkers for breast cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high breast cancer biomarkers market revenue in the coming years.

Although the market is poised to grow in the forthcoming years, the market faces several challenges in terms of reimbursement policies supported by the government. This is further attributed to the high cost of breast cancer treatment, especially in developing nations. Nevertheless, government support in spreading awareness about breast cancer, and the availability of treatment options for the same are likely to create lucrative growth opportunities for the market in the forthcoming years.

Our report provides in-depth analysis on the currently available biomarker across various stages of clinical trial. This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges that will determine the market's future growth.

Table of Contents

1. Global Breast Cancer Antibodies Market

  • 1.1. Current Market Scenario
  • 1.2. Future Market Opportunity

2. Breast Cancer Monoclonal Antibodies - Availability, Patent, Price & Dosage Analysis

  • 2.1. Trastuzumab (Herceptin)
  • 2.2. Trastuzumab Biosimilar (Ontruzant)
  • 2.3. Trastuzumab Biosimilar (Ogivri)
  • 2.4. Trastuzumab Biosimilar (Herzuma)
  • 2.5. Trastuzumab Biosimilar (Trazimera)
  • 2.6. Trastuzumab Biosimilar (Kanjinti)
  • 2.7. Trastuzumab Biosimilar (Zercepac/HLX02)
  • 2.8. Pertuzumab (Perjeta)
  • 2.9. Margetuximab (Margenza)
  • 2.10. Pembrolizumab (Keytruda )
  • 2.11. Atezolizumab (Tecentriq)
  • 2.12. Inetetamab (Cipterbin)

3. Breast Cancer Antibody Drug Conjugates - Availability, Dosage & Price Analysis

  • 3.1. Kadcyla
  • 3.2. Enhertu
  • 3.3. Trodelvy
  • 3.4. Ujvira

4. Combinational Antibodies - Availability, Dosage, Price & Sales Analysis

  • 4.1. Trastuzumab, Pertuzumab, & Hyaluronidase (Phesgo)
  • 4.2. Trastuzumab & Hyaluronidase Injection (Herceptin Hylecta)

5. Breast Cancer Monoclonal Antibodies - Sales Analysis

  • 5.1. Herceptin
  • 5.2. Kanjinti
  • 5.3. Perjeta
  • 5.4. Margenza
  • 5.5. Keytruda
  • 5.6. Tecentriq
  • 5.7. Trazimera
  • 5.8. Phesgo

6. Breast Cancer Antibody Drug Conjugate - Sales Insights

  • 6.1. Kadcyla
  • 6.2. Enhertu
  • 6.3. Trodelvy

7. Breast Cancer Antibodies Biomarkers & Clinical Trials Insight By Company, Indication & Phase

  • 7.1. Research
  • 7.2. Preclinical
  • 7.3. Phase-I
  • 7.4. Phase-I/II
  • 7.5. Phase-II
  • 7.6. Phase-II/III
  • 7.7. Phase-III
  • 7.8. Preregistration
  • 7.9. Registered

8. Marketed Breast Cancer Antibodies Biomarkers Insight

9. Competitive Landscape

  • 9.1. Amgen
  • 9.2. Akesobio
  • 9.3. Beigene
  • 9.4. Gilead Sciences
  • 9.5. Macrogenics
  • 9.6. Merck
  • 9.7. Pfizer
  • 9.8. Roche
  • 9.9. Samsung Bio
  • 9.10. Zydus Cadila

List of Figures

  • Figure 1-1: Global - Breast Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 1-2: Global - Breast Cancer Antibodies Market Size (US$ Billion), 2020 & 2021
  • Figure 1-3: Global - Breast Cancer Antibodies Market by Region (US$ Billion), 2021
  • Figure 1-4: Global - Breast Cancer Antibodies Market by Region (%), 2021
  • Figure 1-5: Global - Breast Cancer Antibodies Market by Product (US$ Billion), 2021
  • Figure 1-6: Global - Breast Cancer Antibodies Market by Product (%), 2021
  • Figure 1-7: Global - Breast Cancer Antibodies Market Size (US$ Billion), 2022 - 2028
  • Figure 1-8: US - Breast Cancer Antibodies Market Size (US$ Billion), 2022 - 2028
  • Figure 2-1: Herceptin - FDA Approval Year by Cancer Type
  • Figure 2-2: Herceptin -Approval Year by Region
  • Figure 2-3: US- Price for a Supply of 10 & Price for Single Herceptin 150mg Powder for Injection (US$), February'2022
  • Figure 2-4: UK- Price for Single Herceptin 150mg Powder for Injection (GBP/US$), February'2022
  • Figure 2-5: Herceptin - Initial & Maintenance Dose for Breast Cancer Treatment (mg/kg)
  • Figure 2-6: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Breast Cancer (US$), February'2022
  • Figure 2-7: Herceptin - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
  • Figure 2-8: Herceptin - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-9: Ontruzant -Approval Year by Region
  • Figure 2-10: US- Price for 150mg & 420mg Ontruzant Powder for Injection (US$), February'2022
  • Figure 2-11: UK- Price for Single Ontruzant 150mg Powder for Injection (GBP/US$), February'2022
  • Figure 2-12: Ontruzant - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
  • Figure 2-13: Ontruzant - Average Cost of Initial Week, Maintenance Week & Annual (US$), February'2022
  • Figure 2-14: Ontruzant - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
  • Figure 2-15: Ontruzant - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-16: Ogivri -Approval Year by Region
  • Figure 2-17: Ogivri - Price for 150mg & 420mg Powder for Injection (US$), February'2022
  • Figure 2-18: Ogivri - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
  • Figure 2-19: Ogivri - Average Cost of Initial Week, Maintenance Week & Annual (US$), February'2022
  • Figure 2-20: Ogivri - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
  • Figure 2-21: Ogivri - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-22: Herzuma -Approval Year by Region
  • Figure 2-23: US- Price for 150mg & 420mg Herzuma Powder for Injection (US$), February'2022
  • Figure 2-24: UK- Price for 150mg & 420mg Herzuma Powder for Injection (GBP/US$), February'2022
  • Figure 2-25: Herzuma - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
  • Figure 2-26: Herzuma - Average Cost of Initial Week, Maintenance Week & Annual (US$), February'2022
  • Figure 2-27: Herzuma - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
  • Figure 2-28: Herzuma - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-29: Trazimera -Approval Year by Region
  • Figure 2-30: US- Price for 150mg & 420mg Trazimera Powder for Injection (US$), February'2022
  • Figure 2-31: UK- Price for 150mg & 420mg Trazimera Powder for Injection (GBP/US$), February'2022
  • Figure 2-32: Trazimera - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
  • Figure 2-33: Trazimera - Average Cost of Initial Week, Maintenance Week & Annual treatment (US$), February'2022
  • Figure 2-34: Trazimera - Initial & Maintenance Dose for Adjuvant Breast Cancer (mg/kg)
  • Figure 2-35: Trazimera - Cost of Initial Dose, Maintenance Dose & Annual Treatment Cost of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-36: Kanjinti -Approval Year by Region
  • Figure 2-37: US - Price for 150mg & 420mg Powder for Injection (US$), February'2022
  • Figure 2-38: UK- Price for 150mg & 420mg Kanjinti Powder for Injection (GBP/US$), February'2022
  • Figure 2-39: Kanjinti - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
  • Figure 2-40: Kanjinti - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), February'2022
  • Figure 2-41: Kanjinti - Initial & Maintenance Dose for of Adjuvant Breast Cancer (mg/kg/Week)
  • Figure 2-42: Kanjinti - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-43: UK- Price for Single Zercepac 150mg Powder for Injection (GBP/US$), February'2022
  • Figure 2-44: Zercepac - Initial & Maintenance Dose for Breast Cancer (mg/kg/Week)
  • Figure 2-45: Zercepac - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Breast Cancer (US$), February'2022
  • Figure 2-46: Zercepac - Initial & Maintenance Dose for of Adjuvant Breast Cancer (mg/kg/Week)
  • Figure 2-47: Zercepac - Average Cost of Initial Week, Maintenance Week & Annual Treatment of Adjuvant Breast Cancer (US$), February'2022
  • Figure 2-48: Perjeta - Approval Year by Region
  • Figure 2-49: Perjeta - FDA Approval Year by Cancer Type
  • Figure 2-50: Perjeta - Patent Expiration Year by Region
  • Figure 2-51: US- Price for a Supply of 14 ml and Price Per ml of Perjeta Intravenous Solution (US$), February'2022
  • Figure 2-52: UK- Price for a Supply of 14 ml and Price Per ml of Perjeta Intravenous Solution (GBP/US$), February'2022
  • Figure 2-53: Perjeta - Initial & Maintenance Dose for Breast Cancer Treatment (mg/3 weeks)
  • Figure 2-54: Perjeta - Minimum & Maximum Treatment Cost for Breast Cancer (US$), February'2022
  • Figure 2-55: Perjeta - Minimum & Maximum Treatment Cost of Neoadjuvant Breast Cancer Treatment (US$), February'2022
  • Figure 2-56: Margenza - Price for a Supply of 10 ml and Price Per ml of Intravenous Solution (US$), February'2022
  • Figure 2-57: Margenza - Price for a Supply of 40 ml and Price Per ml of Intravenous Solution (US$), February'2022
  • Figure 2-58: Margenza - Average Cost of Single Cycle & Annual Treatment (US$), February'2022
  • Figure 2-59: Keytruda - Approval Year by Region
  • Figure 2-60: Keytruda - FDA Approval Year by Indication
  • Figure 2-61: Keytruda - Patent Expiration Year by Region
  • Figure 2-62: US - Price for 4ml, 8ml Supply & Price Per ml of Keytruda Intravenous Injection (US$), February'2022
  • Figure 2-63: UK - Price for 4ml & Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), February'2022
  • Figure 2-64: Keytruda - Duration of Single Treatment Cycle & Full Treatment of Melanoma & Other Cancers (Weeks), February'2022
  • Figure 2-65: Keytruda - Cost of Single & Full Treatment using Solution of Injection (US$), February'2022
  • Figure 2-66: Tecentriq - Approval Year by Region
  • Figure 2-67: Tecentriq - FDA Approval Year by Indication
  • Figure 2-68: US- Price for 14ml Supply & Price Per ml of Tecentriq 840mg/14ml Intravenous Injection (US$), February'2022
  • Figure 2-69: US - Price for 20ml Supply & Price Per ml of Tecentriq 1200mg/20ml Intravenous Injection (US$), February'2022
  • Figure 2-70: UK- Price for a Supply of 20ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), February'2022
  • Figure 2-71: UK- Price for a Supply of 14ml & Price Per ml of Tecentriq Solution for Injection (GBP/US$), February'2022
  • Figure 2-72: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 840mg/2 Week Dose (US$), February'2022
  • Figure 2-73: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1200mg/3 Week Dose (US$), February'2022
  • Figure 2-74: Tecentriq - Average Cost of Single Treatment Cycle & Annual Treatment using 1680mg/4 Week Dose (US$), February'2022
  • Figure 3-1: US - Kadcyla FDA Approval Year by Indication
  • Figure 3-2: Kadcyla - Approval Year by Region
  • Figure 3-3: US - Kadcyla FDA Approval & Patent Expiration Year
  • Figure 3-4: US - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (US$), January'2022
  • Figure 3-5: UK - Price for Single Unit of Kadcyla 100mg & 160mg Intravenous Powder for Injection (GBP/US$), January'2022
  • Figure 3-6: Kadcyla - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
  • Figure 3-7: Kadcyla - Average Cost of Single Treatment Cycle & Full Treatment of Early Stage HER2 Breast Cancer in Human with Average Weight (US$), January'2022
  • Figure 3-8: Kadcyla - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
  • Figure 3-9: US - Enhertu Orphan Drug Designation Approval & Exclusivity Year
  • Figure 3-10: Enhertu - Approval Year by Region
  • Figure 3-11: US - Polivy FDA Approval Year by Indication
  • Figure 3-12: UK - Cost of Supply of Enhertu 100mg Intravenous Powder (GBP/US$), January'2022
  • Figure 3-13: Besponsa - Cost of Supply of Vial for Injection by Region (US$), January'2022
  • Figure 3-14: Enhertu - Recommended Dose by Cancer Type (mg/Kg)
  • Figure 3-15: Enhertu - Average Cost of Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 3-16: Enhertu - Recommended Dose & Dose after Reduction for Breast Cancer (mg/Kg)
  • Figure 3-17: Enhertu - Recommended Dose & Dose after Reduction for Gastric Cancer (mg/Kg)
  • Figure 3-18: US - Trodelvy FDA Approval by Indication
  • Figure 3-19: Trodelvy - Approval Year by Region
  • Figure 3-20: Trodelvy - Patent Expiration by Region
  • Figure 3-21: Trodelvy - Average Cost of Single Dose, Single Treatment Cycle & Annual Treatment Cost (US$), January'2022
  • Figure 3-22: Trodelvy - Recommended Dose & Dose after Reduction (mg/Kg)
  • Figure 3-23: India - Price for Single Unit of Ujvira 100mg & 160mg Intravenous Powder for Injection (INR/US$), January'2022
  • Figure 3-24: India - Price for Single Unit of Branded & Biosimilar Trastuzumab Emtansine 100mg Powder for Injection (INR/US$), January'2022
  • Figure 3-25: Ujvira - Duration of Single Treatment Cycle & Full Treatment of Early Stage HER2+ Breast Cancer (Weeks)
  • Figure 3-26: Ujvira - Recommended Dose After 1st & 2nd Dose Reduction (mg/m2)
  • Figure 4-1: Phesgo - Price for various Supplies of Subcutaneous Solution for Injection (US$), February'2022
  • Figure 4-2: Phesgo - Duration of Treatment by Type (Cycles)
  • Figure 4-3: Herceptin Hylecta - Price for 5ml & Price Per ml of Subcutaneous Solution for Injection (US$), February'2022
  • Figure 4-4: Herceptin Hylecta - Duration of Single Treatment Cycle & Full Treatment (week)
  • Figure 5-1: Global - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-2: US - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-3: Europe - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-4: Japan - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-5: ROW - Herceptin Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-6: Herceptin - Annual Sales Value by Region (US$/CHF Million), 2021
  • Figure 5-7: Herceptin - Annual Sales Value by Region (%), 2021
  • Figure 5-8: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 5-9: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 5-10: Global - Kanjinti Annual Sales (US$ Million), 2019 - 2021
  • Figure 5-11: US - Kanjinti Annual Sales (US$ Million), 2019 - 2021
  • Figure 5-12: Kanjinti - Annual Sales by Region (US$ Million), 2021
  • Figure 5-13: Kanjinti - Annual Sales by Region (%), 2021
  • Figure 5-14: Global - Kanjinti Quarterely Sales (US$ Million), 2021
  • Figure 5-15: US - Kanjinti Quarterely Sales (US$ Million), 2021
  • Figure 5-16: Global - Kanjinti Quarterely Sales (US$ Million), 2020
  • Figure 5-17: US - Kanjinti Quarterely Sales (US$ Million), 2020
  • Figure 5-18: Global - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-19: US - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-20: Europe - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-21: Japan - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-22: ROW - Perjeta Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-23: Perjeta - Annual Sales Value by Region (US$/CHF Million), 2021
  • Figure 5-24: Perjeta - Annual Sales Value by Region (%), 2021
  • Figure 5-25: US - Perjeta Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 5-26: Global - Margenza Quarterly Sales (US$ Million), 2021
  • Figure 5-27: Global - Keytruda Annual Sales Value (US$ Billion), 2018 - 2021
  • Figure 5-28: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021
  • Figure 5-29: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020
  • Figure 5-30: Global - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 531: US - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-32: Europe - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-33: Japan - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-34: ROW - Tecentriq Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 5-35: Tecentriq - Annual Sales Value by Region (US$/CHF Million), 2021
  • Figure 5-36: Tecentriq - Annual Sales Value by Region (%), 2021
  • Figure 5-37: Global - Tecentriq Quarterly Sales Value (US$ Billion), 2021
  • Figure 5-38: US - Tecentriq Quarterly Sales Value (US$ Billion), 2021
  • Figure 5-39: US - Tecentriq Quarterly Sales Value (US$ Million), 2020
  • Figure 5-40: Global - Trazimera Annual Sales (US$ Million), 2020 & 2021
  • Figure 5-41: US - Trazimera Annual Sales (US$ Million), 2020 & 2021
  • Figure 5-42: Europe - Trazimera Annual Sales (US$ Million), 2020 & 2021
  • Figure 5-43: Trazimera - Annual Sales by Region (US$ Million), 2021
  • Figure 5-44: Trazimera - Annual Sales by Region (US$ Million), 2020
  • Figure 5-45: Trazimera - Annual Sales by Region (%), 2021
  • Figure 5-46: Trazimera - Annual Sales by Region (%), 2020
  • Figure 5-47: Global - Phesgo Annual Sales Value (US$/CHF Million), 2020 & 2021
  • Figure 5-48: Phesgo - Annual Sales Value by Region (US$/CHF Million), 2021
  • Figure 5-49: Phesgo - Annual Sales Value by Region (%), 2021
  • Figure 5-50: Global - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 5-51: US - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 5-52: Europe - Phesgo Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 6-1: Global - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 6-2: US - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 6-3: Europe - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 6-4: Japan - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 6-5: ROW - Kadcyla Annual Sales Value (US$/CHF Million), 2019 - 2021
  • Figure 6-6: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2021
  • Figure 6-7: Kadcyla - Annual Sales Value by Region (%), 2021
  • Figure 6-8: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 6-9: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 6-10: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 6-11: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 6-12: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2021
  • Figure 6-13: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 6-14: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 6-15: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 6-16: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 6-17: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2020
  • Figure 6-18: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2020
  • Figure 6-19: Kadcyla - Annual Sales Value by Region (%). 2020
  • Figure 6-20: Global - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 6-21: US - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 6-22: Europe - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 6-23: Japan - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 6-24: ROW - Kadcyla Quarterly Sales Value (US$/CHF Million), 2019
  • Figure 6-25: Kadcyla - Annual Sales Value by Region (US$/CHF Million), 2019
  • Figure 6-26: Global - Enhertu Annual Sales (US$ Million), 2020 & 2021
  • Figure 6-27: Global - Enhertu Quarterly Sales (US$ Million), 2021
  • Figure 6-28: Global - Enhertu Quarterly Sales (US$ Million), 2020
  • Figure 6-29: Global - Trodelvy Annual Sales (US$ Million), 2020 & 2021
  • Figure 6-30: Global - Trodelvy Quarterly Sales (US$ Million), 2021
  • Figure 6-31: Trodelvy - Annual Sales by Region (US$ Million), 2021
  • Figure 6-32: Trodelvy - Annual Sales by Region (%), 2021